MDT GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Medtronic Plc
Exchange: NYSESector: HealthcareIndustry: Medical Devices
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery. About Medtronic Bold thinking. Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
Did you know?
Free cash flow has been growing at -2.1% annually.
Current Price
$78.30
-2.13%GoodMoat Value
$53.32
31.9% overvaluedProfile
Valuation (TTM)
Market Cap$100.38B
P/E21.76
EV$131.44B
P/B2.09
Shares Out1.28B
P/Sales2.83
Revenue$35.48B
EV/EBITDA12.87
Medtronic Plc (MDT) Quality Analysis
GoodMoat Analysis
Medtronic exhibits a moderate competitive position with a durable, but not exceptional, moat. Its quality profile is adequate, showing stable profitability and a solid balance sheet, but key returns on capital are below the high-quality thresholds for a value investor.
Read full analysis
Medtronic's quality profile is mixed, showing stability but not the high returns typical of a premium compounder. The business is profitable, with a 13.0% profit margin and a 17.8% operating margin, and generates a 4.6% free cash flow yield. However, its Return on Equity (ROE) of 9.6% falls well below the framework's high-quality threshold of 15-20%, indicating capital is not being deployed with exceptional efficiency. The balance sheet is a strength, with a moderate Debt/Equity ratio of 0.59, supporting financial flexibility. Revenue growth of 8.7% YoY is positive but modest. In terms of moat, Medtronic likely scores on criteria like switching costs (mission-critical medical devices), regulatory barriers, and niche dominance in certain therapy areas, but it lacks the explosive growth and technology leadership seen in higher-moat innovators. Compared to peers, its profitability and growth are stable but not outstanding, reflecting its position as a large, mature industry leader rather than a dynamic high-quality grower. The quality indicators point to an adequate, financially sound business, but not one that clearly exceeds the high benchmarks for returns on capital and growth sought in the framework.
MDT Profitability
Profitability trend analysis coming soon
MDT Growth
Growth trend analysis coming soon
MDT Financial Health
Financial health indicators coming soon
MDT Quality & Fundamental Analysis
Medtronic Plc (MDT) is a Healthcare company in the Medical Devices industry, listed on NYSE. This quality analysis page evaluates Medtronic Plc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Medtronic Plc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 13.00% and a return on equity (ROE) of 9.61%. Return on assets (ROA) stands at 5.03%.
The debt-to-equity ratio is 0.59, with a current ratio of 1.85. Operating margin is 17.76%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Medtronic Plc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.